Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding trial of obeticholic acid in primary sclerosing cholangitis
2014-002205-38Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of obeticholic acid in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by Intercept Pharmaceuticals. Primary endpoint: Change in alkaline phosphatase from baseline to week 24. Started Feb 2018; status: completed.
02
Drugs
obeticholic acid
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2014-002205-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002205-38.